Q2 2024 13F Holders as of 6/30/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
145M
-
Number of holders
-
202
-
Total 13F shares, excl. options
-
120M
-
Shares change
-
+4.2M
-
Total reported value, excl. options
-
$2.78B
-
Value change
-
+$111M
-
Put/Call ratio
-
0.3
-
Number of buys
-
109
-
Number of sells
-
-92
-
Price
-
$23.22
Significant Holders of Denali Therapeutics Inc. - Common Stock (DNLI) as of Q2 2024
245 filings reported holding DNLI - Denali Therapeutics Inc. - Common Stock as of Q2 2024.
Denali Therapeutics Inc. - Common Stock (DNLI) has 202 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 120M shares
of 145M outstanding shares and own 82.35% of the company stock.
Largest 10 shareholders include BAILLIE GIFFORD & CO (13.8M shares), BlackRock Inc. (13.2M shares), VANGUARD GROUP INC (11.3M shares), WELLINGTON MANAGEMENT GROUP LLP (9.82M shares), Capital Research Global Investors (7.13M shares), Temasek Holdings (Private) Ltd (5.71M shares), Crestline Management, LP (4.76M shares), STATE STREET CORP (4.43M shares), TAKEDA PHARMACEUTICAL CO LTD (4.21M shares), and BAKER BROS. ADVISORS LP (3.73M shares).
This table shows the top 202 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.